Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported final results from its pivotal Phase III STRIVE study showing that cystic fibrosis (CF) patients treated with VX-770 showed rapid improvements in lung function that were sustained through 48 weeks compared to placebo. Results showed a mean absolute improvement in lung function of 10.6 percent through week 24 and 10.5 percent through week 48.